Rebecca Reece1, Allison Delong2, D'Antuono Matthew3, Karen Tashima3, Rami Kantor3. 1. Division of Infectious Diseases, Brown University Alpert Medical School, 164 Summit Avenue, Providence RI 02906, USA. Electronic address: rreece@lifespan.org. 2. Center for Statistical Sciences, Brown University, Providence RI, USA. 3. Division of Infectious Diseases, Brown University Alpert Medical School, 164 Summit Avenue, Providence RI 02906, USA.
Abstract
BACKGROUND: One-pill-once-a-day regimens (OPODs) appeal to providers and patients. The impact of resistance to OPODs in routine clinical care is important yet unclear, particularly in treatment-experienced patients. OBJECTIVES: We hypothesized that resistance to any OPOD component impacts treatment success and that historical, vs. most recent, resistance better predicts it. STUDY DESIGN: In the largest RI HIV Center, we identified all patients starting/switching to Complera/Stribild, evaluated their 12-month viral load (VL) suppression, and examined the impact of demographic, clinical and laboratory data on it, focusing on recent-only vs. accumulated significant resistance, defined as low-, intermediate- or high-level predicted resistance to any OPOD component. Associations with outcomes were evaluated using Fisher exact and Wilcoxon rank sum tests. Hypotheses were tested using logistic regression. RESULTS: Of 1624 patients, 224 started/switched to Complera or Stribild, mean age 44 years, 8 years post-diagnosis, CD4 468 cells/μL; 183 treatment-experienced (140 with genotypes; 61% suppressed at switch). Significant OPOD-associated resistance was in 30% by recent-only genotypes, and 38% by all genotypes. 12-month VL suppression was in 83% of treatment-experienced participants: 96% of suppressed at switch, associated with older age, higher CD4, fewer prior genotypes, less accumulated resistance, and better adherence; and 61% of unsuppressed at switch, associated with better adherence. Accumulated resistance independently predicted 12-month failure, better than most-recent resistance only. CONCLUSION: 12-month VL suppression with Complera/Stribild was high, suggesting that OPODs remain options even for experienced patients. Clinicians should consider resistance history before switching to OPODs and continue to focus on improving adherence.
BACKGROUND: One-pill-once-a-day regimens (OPODs) appeal to providers and patients. The impact of resistance to OPODs in routine clinical care is important yet unclear, particularly in treatment-experienced patients. OBJECTIVES: We hypothesized that resistance to any OPOD component impacts treatment success and that historical, vs. most recent, resistance better predicts it. STUDY DESIGN: In the largest RI HIV Center, we identified all patients starting/switching to Complera/Stribild, evaluated their 12-month viral load (VL) suppression, and examined the impact of demographic, clinical and laboratory data on it, focusing on recent-only vs. accumulated significant resistance, defined as low-, intermediate- or high-level predicted resistance to any OPOD component. Associations with outcomes were evaluated using Fisher exact and Wilcoxon rank sum tests. Hypotheses were tested using logistic regression. RESULTS: Of 1624 patients, 224 started/switched to Complera or Stribild, mean age 44 years, 8 years post-diagnosis, CD4 468 cells/μL; 183 treatment-experienced (140 with genotypes; 61% suppressed at switch). Significant OPOD-associated resistance was in 30% by recent-only genotypes, and 38% by all genotypes. 12-month VL suppression was in 83% of treatment-experienced participants: 96% of suppressed at switch, associated with older age, higher CD4, fewer prior genotypes, less accumulated resistance, and better adherence; and 61% of unsuppressed at switch, associated with better adherence. Accumulated resistance independently predicted 12-month failure, better than most-recent resistance only. CONCLUSION: 12-month VL suppression with Complera/Stribild was high, suggesting that OPODs remain options even for experienced patients. Clinicians should consider resistance history before switching to OPODs and continue to focus on improving adherence.
Authors: Allison K Delong; Mingham Wu; Diane Bennett; Neil Parkin; Zhijin Wu; Joseph W Hogan; Rami Kantor Journal: AIDS Res Hum Retroviruses Date: 2011-10-26 Impact factor: 2.205
Authors: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: P Richard Harrigan; Brian Wynhoven; Zabrina L Brumme; Chanson J Brumme; Beheroze Sattha; Jennifer C Major; Rafael de la Rosa; Julio S G Montaner Journal: J Infect Dis Date: 2005-03-16 Impact factor: 5.226
Authors: Frank J Palella; Martin Fisher; Pablo Tebas; Brian Gazzard; Peter Ruane; Jan Van Lunzen; David Shamblaw; Jason Flamm; Ramin Ebrahimi; Danielle Porter; Kirsten White; Jason Hindman; Elizabeth Elbert; Shampa De-Oertel; Todd Fralich Journal: AIDS Date: 2014-01-28 Impact factor: 4.177
Authors: Anthony M Mills; Calvin Cohen; Edwin Dejesus; Cynthia Brinson; Scott Williams; Kitty L Yale; Srini Ramanathan; Maggie H Wang; Kirsten White; Susan K Chuck; Andrew K Cheng Journal: HIV Clin Trials Date: 2013 Sep-Oct
Authors: Hans-Juergen Stellbrink; Andrea Antinori; Anton Pozniak; Jason Flamm; Fritz Bredeek; Kiran Patel; Will Garner; David Piontkowsky Journal: J Int AIDS Soc Date: 2014-11-02 Impact factor: 5.396
Authors: Joseph Gathe; Jose R Arribas; Jan Van Lunzen; Will Garner; Rebecca M Speck; Randall Bender; Sanatan Shreay; Thai Nguyen Journal: Patient Date: 2015-10 Impact factor: 3.883
Authors: Vlad Novitsky; Jon Steingrimsson; Mark Howison; Casey Dunn; Fizza S Gillani; Akarsh Manne; Yuanning Li; Matthew Spence; Zoanne Parillo; John Fulton; Theodore Marak; Philip Chan; Thomas Bertrand; Utpala Bandy; Nicole Alexander-Scott; Joseph Hogan; Rami Kantor Journal: AIDS Date: 2021-09-01 Impact factor: 4.632